<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">20550222</PMID>
        <DateCompleted>
            <Year>2010</Year>
            <Month>10</Month>
            <Day>29</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1179-2027</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>28</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2010</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PharmacoEconomics</Title>
                <ISOAbbreviation>Pharmacoeconomics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Impact of rapid methicillin-resistant Staphylococcus aureus polymerase chain reaction testing on mortality and cost effectiveness in hospitalized patients with bacteraemia: a decision model.</ArticleTitle>
            <Pagination>
                <MedlinePgn>567-75</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.2165/11533020-000000000-00000</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patients hospitalized with Staphylococcus aureus bacteraemia have an unacceptably high mortality rate. Literature available to date has shown that timely selection of the most appropriate antibacterial may reduce mortality. One tool that may help with this selection is a polymerase chain reaction (PCR) assay that distinguishes methicillin (meticillin)-resistant S. aureus (MRSA) from methicillin-susceptible S. aureus (MSSA) in less than 1 hour. To date, no information is available evaluating the impact of this PCR technique on clinical or economic outcomes.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the effect of a rapid PCR assay on mortality and economics compared with traditional empiric therapy, using a literature-derived model.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A literature search for peer-reviewed European (EU) and US publications regarding treatment regimens, outcomes and costs was conducted. Information detailing the rates of infection, as well as the specificity and sensitivity of a rapid PCR assay (Xpert MRSA/SA Blood Culture PCR) were obtained from the peer-reviewed literature. Sensitivity analysis varied the prevalence rate of MRSA from 5% to 80%, while threshold analysis was applied to the cost of the PCR test. Hospital and testing resource consumption were valued with direct medical costs, adjusted to year 2009 values. Adjusted life-years were determined using US and WHO life tables. The cost-effectiveness ratio was defined as the cost per life-year saved. Incremental cost-effectiveness ratios (ICERs) were calculated to determine the additional cost necessary to produce additional effectiveness. All analyses were performed using TreeAge Software (2008).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean mortality rates were 23% for patients receiving empiric vancomycin subsequently switched to semi-synthetic penicillin (SSP) for MSSA, 36% for patients receiving empiric vancomycin treatment for MRSA, 59% for patients receiving empiric SSP subsequently switched to vancomycin for MRSA and 12% for patients receiving empiric SSP for MSSA. Furthermore, with an MRSA prevalence of 30%, the numbers of patients needed to test in order to save one life were 14 and 16 compared with empiric vancomycin and SSP, respectively. The absolute mortality difference for MRSA prevalence rates of 80% and 5% favoured the PCR testing group at 2% and 10%, respectively, compared with empiric vancomycin and 18% and 1%, respectively, compared with empiric SSP. In the EU, the cost-effectiveness ratios for empiric vancomycin- and SSP-treated patients were Euro 695 and Euro 687 per life-year saved, respectively, compared with Euro 636 per life-year saved for rapid PCR testing. In the US, the cost-effectiveness ratio was $US 898 per life-year saved for empiric vancomycin and $US 820 per life-year saved for rapid PCR testing. ICERs demonstrated dominance of the PCR test in all instances. Threshold analysis revealed that PCR testing would be less costly overall, even at greatly inflated assay prices.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Rapid PCR testing for MRSA appears to have the potential to reduce mortality rates while being less costly than empiric therapy in the EU and US, across a wide range of MRSA prevalence rates and PCR test costs.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Brown</LastName>
                    <ForeName>Jack</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>State University of New York at Buffalo, School of Pharmacy and Pharmaceutical Science, Buffalo, New York 14260, USA. JB322@Buffalo.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Paladino</LastName>
                    <ForeName>Joseph A</ForeName>
                    <Initials>JA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>New Zealand</Country>
            <MedlineTA>Pharmacoeconomics</MedlineTA>
            <NlmUniqueID>9212404</NlmUniqueID>
            <ISSNLinking>1170-7690</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>T</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016470" MajorTopicYN="N">Bacteremia</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
                <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017048" MajorTopicYN="Y">Health Care Costs</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName>
                <QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055624" MajorTopicYN="N">Methicillin-Resistant Staphylococcus aureus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009026" MajorTopicYN="N">Mortality</DescriptorName>
                <QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName>
                <QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013203" MajorTopicYN="N">Staphylococcal Infections</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
                <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>6</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>6</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>10</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20550222</ArticleId>
            <ArticleId IdType="pii">3</ArticleId>
            <ArticleId IdType="doi">10.2165/11533020-000000000-00000</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Infect Control Hosp Epidemiol. 1999 Jun;20(6):408-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10395142</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2006 Sep 2;368(9538):874-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16950365</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pharmacotherapy. 1997 Sep-Oct;17(5):990-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9324187</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Med. 2006 Nov;119(11):943-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17071162</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 1999 Nov 10;282(18):1745-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10568647</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Expert Opin Pharmacother. 2004 Sep;5(9):1867-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15330725</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2007 Oct;51(10):3731-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17664322</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Microbiol Infect. 2007 Mar;13(3):264-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17391380</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Diagn Microbiol Infect Dis. 2005 Jun;52(2):113-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15964499</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Infect Control Hosp Epidemiol. 2005 Feb;26(2):166-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15756888</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Infect Dis. 2003 Jan 1;36(1):53-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12491202</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Microbiol. 2009 Mar;47(3):823-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19144803</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Infect Dis. 2000 Feb;30(2):368-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10671343</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Infect Dis. 1995 Dec;21(6):1417-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8749626</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
